At the IGTP TODAY

News

- Innovation

Researchers at Can Ruti Campus enter into a licence agreement for the worldwide rights to the use of biomarker soluble neprilysin (sNEP) for assessing risk stratification and prognosis of heart failure patients

23 April 2016.  The group led by Dr Antoni Bayés-Genís of the Department of Cardiology of the Germans Trias i Pujol Hospital (HUGTiP) and the Germans Trias i Pujol Health Research Institute (IGTP) have signed a licence agreement with the American Company Critical Diagnostics for biomarker soluble neprilysin (sNEP).